Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Diazoxide (Proglycem) 是一种 ATP 敏感性的钾离子通道激活剂,是一种苯并噻二嗪衍生物,是一种用于高血压急症的外周血管扩张剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
100 mg | ¥ 415 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 373 | 现货 |
产品描述 | Diazoxide (Proglycem) is a benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. |
体外活性 | Diazoxide inhibits microglial inflammatory activity. Diazoxide treatment partially inhibits the inflammatory pattern induced by LPS/IFN-γ in microglial cells, inducing a decrease in NO production that could be because of the decreased expression of iNOS detected. Diazoxide has no effect on microglial phagocytosis[1]. |
体内活性 | Diazoxide is beneficial on the improvement in cognitive tasks, reduction of anxiety, decrease in the accumulation of amyloid-beta oligomers and hyperphosphorylation of tau proteins. Diazoxide may also exerts neuroprotective effects independently of K+ channel activation by decreasing neuronal excitability and activation of N-methyl-D-aspartate (NMDA) receptors or by increasing currents trough α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Diazoxide-treated animals show a decrease in disease severity a few days after the first clinical signs are observed, corresponding to the acute inflammatory phase of the disease. Daily oral administration of diazoxide in EAE mice during the effector phase of the disease reduces the severity of the clinical signs without any apparent adverse effect. Diazoxide decreases demyelination and axonal loss, reduces tissue damage, inhibits microglial/macrophage and astrocytic activation and preserves neuron integrity. No effects are observed on the number of B and T lymphocytes infiltrating the spinal cord[1]. |
细胞实验 | The phagocytic ability of microglia is determined by the uptake of 2-μm red fluorescent microspheres by BV-2 cells. Cells are treated with diazoxide 100 μM and activated with LPS/IFN-γ and then incubated with microspheres at a concentration of 0.01% for 30 min in the dark at 37°C and 5% CO2. Cells are rinsed twice in PBS solution, pelleted at 1,000 g for 5 min and resuspended in 300 μL PBS. Cells are kept on ice and analyzed by flow cytometry.(Only for Reference) |
别名 | 氯甲苯噻嗪, 二氮嗪, SRG-95213, Sch-6783, Proglycem |
分子量 | 230.67 |
分子式 | C8H7ClN2O2S |
CAS No. | 364-98-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 43 mg/mL (186.4 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.3352 mL | 21.676 mL | 43.352 mL | 108.3799 mL |
5 mM | 0.867 mL | 4.3352 mL | 8.6704 mL | 21.676 mL | |
10 mM | 0.4335 mL | 2.1676 mL | 4.3352 mL | 10.838 mL | |
20 mM | 0.2168 mL | 1.0838 mL | 2.1676 mL | 5.419 mL | |
50 mM | 0.0867 mL | 0.4335 mL | 0.867 mL | 2.1676 mL | |
100 mM | 0.0434 mL | 0.2168 mL | 0.4335 mL | 1.0838 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Diazoxide 364-98-7 Autophagy Membrane transporter/Ion channel ATPase Potassium Channel Sch6783 氯甲苯噻嗪 SRG 95213 inhibit Inhibitor 二氮嗪 SRG95213 SRG-95213 Sch-6783 Sch 6783 KcsA Proglycem inhibitor